Pharming Group (NASDAQ:PHAR) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Pharming Group (NASDAQ:PHAR) issued its earnings results on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02), Zacks reports. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Pharming Group updated its FY 2025 guidance to EPS.

Pharming Group Stock Performance

Pharming Group stock traded up $1.33 during mid-day trading on Thursday, reaching $9.07. 10,123 shares of the company were exchanged, compared to its average volume of 6,131. The firm has a market cap of $617.04 million, a PE ratio of -34.82 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The firm’s 50-day simple moving average is $9.05 and its two-hundred day simple moving average is $8.57. Pharming Group has a twelve month low of $6.65 and a twelve month high of $11.80.

Wall Street Analysts Forecast Growth

PHAR has been the topic of a number of research reports. Jefferies Financial Group began coverage on Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.